Live on XaptiqUGC NET Economics (Dec 2026) and IIT JAM Economics (EN) test series are now live on Xaptiq.View test series
OpinionHealth > Drug PricingMicroeconomicsMarket StructuresSubsidies

Margin cap on 137 cancer drugs takes effect November 9, but bills may not fall

Trade margins on 137 cancer drugs will be capped at 30% of the retail price from November 9, with prices expected to fall up to 70%. The real test is whether patients' bills fall, argues pharmacologist Y K Gupta.

What happened

The National Pharmaceutical Pricing Authority (NPPA) has brought 137 non-scheduled anti-cancer drugs under Trade Margin Rationalisation (TMR), effective November 9. TMR caps the margin that distributors and retailers can add, here at 30% of the maximum retail price (MRP), excluding GST. MRPs are expected to fall by up to 70%. The reform must be judged by what it does to patients' bills, argues Y K Gupta, President of AIIMS Kalyani and former dean of AIIMS, New Delhi.

Context

The NPPA found mark-ups of up to 700% on some anti-cancer medicines. Per-dose prices of pemetrexed ranged from Rs 546 to over Rs 72,000, and bevacizumab from about Rs 6,900 to Rs 1.18 lakh. The list covers blood, lung, breast, prostate, gastrointestinal and ovarian cancers. It also includes patented immunotherapy drugs whose prices the Drugs Prices Control Order does not normally regulate, such as pembrolizumab, priced at about Rs 2.06 lakh per dose. A 2019 TMR pilot on 42 drugs cut MRPs of 526 brands by up to 90%, saving about Rs 984 crore a year.

Why it matters

Capping trade margins targets the distribution chain, not the drug maker. Gupta gives a hypothetical: a medicine sold to a stockist for Rs 10,000 with an MRP of Rs 50,000 leaves a Rs 40,000 gap for intermediaries, distribution and taxes. TMR recalculates the permissible MRP, so the manufacturer's earnings stay the same. That answers the worry that price cuts will hurt innovation.

The pressure falls on those who live off retail mark-ups. Hospitals rely on them, and Nuvama estimates a hit of around 4% for Max Healthcare and 1-2% for other large chains. Hospital EBITDA, operating profit before depreciation, could fall 1-5%. Gupta warns hospitals may recover the loss through higher charges for consultations, diagnostics or packages, so savings on medicines need not mean lower bills.

Two other risks need watching. Associations of small manufacturers fear for jobs and supply in remote areas, so stock-outs of low-cost older drugs must be monitored. And chemists need clear rules for existing stock carrying older, higher MRPs. Gupta asks the NPPA to track actual patient bills, medicine availability and hospital billing after implementation.

Impact for India

  • Cancer patients: MRPs on 137 drugs should fall by up to 70%, but savings depend on hospitals not raising other charges.
  • Hospitals: EBITDA could fall 1-5%, around 4% for Max Healthcare by Nuvama's estimate.
  • Manufacturers: realisations are unchanged in principle; small manufacturers fear for jobs and supply.
  • Chemists: more than 12 lakh retailers and distributors, through their national body, welcomed the move but need guidance on old stock.
  • Health spending: the policy's success should be measured by out-of-pocket spending, which needs post-implementation study.

Key data

Drugs under trade margin cap: 137 non-scheduled anti-cancer drugs2019 pilot: 42 drugs
Margin cap: 30% of MRP, excluding GSTMark-ups up to 700% found
Expected MRP reduction: Up to 70%2019 pilot: up to 90%, saving about Rs 984 crore a year
Estimated hit to hospital EBITDA: 1-5%Max Healthcare around 4% (Nuvama)

Concepts

Trade marginThe difference between the price at which a manufacturer sells and the price the patient pays, shared among distributors and retailers.TMR caps it at 30% of MRP for 137 cancer drugs.
Non-scheduled drugsMedicines outside the national list whose ceiling prices are fixed under the Drugs Prices Control Order.The 137 cancer drugs are non-scheduled, so TMR caps margins rather than fixing prices.
Out-of-pocket expenditureHealth spending paid directly by patients rather than through insurance or government.Gupta argues the policy should be judged by whether this falls.

Theory lens

Mark-up pricing — where buyers have little choice and little information, sellers can set price as cost plus a wide mark-up instead of a competitive margin. A cancer patient prescribed a specific drug cannot shop around, which explains mark-ups of up to 700%. TMR regulates the mark-up rather than the manufacturer's price, but Gupta's concern is that hospitals with market power over a captive patient may shift the mark-up to other charges instead.

Stakeholders

Gains: Cancer patientsMRPs on 137 drugs are expected to fall by up to 70% from November 9.
Pressure point: Hospital chainsLower retail mark-ups could cut EBITDA by 1-5%.
Pressure point: Distributors and retailersMargins are capped at 30% of MRP where mark-ups reached 700%.

Practice Question — from the story

With reference to trade margin rationalisation of anti-cancer drugs, consider the following statements:

  1. It fixes the manufacturer's selling price for the 137 covered drugs.
  2. It caps the trade margin on the covered drugs at 70% of the maximum retail price.

Which of the statements given above is/are correct?

  1. 1 only
  2. 2 only
  3. Both 1 and 2
  4. Neither 1 nor 2
Reveal answer & explanation

Answer: Neither 1 nor 2

  • Statement 1: Incorrect. TMR caps the trade margin and recalculates the permissible MRP; the manufacturer's earnings remain unchanged.
  • Statement 2: Incorrect. The margin is capped at 30% of MRP; 70% is the expected maximum fall in MRPs.

Therefore, the correct answer is Neither 1 nor 2.

Concept check — test your understanding

Why might a cap on medicine trade margins fail to lower a hospital patient's total bill?

  1. Because manufacturers can raise their selling price to distributors to restore the old MRP.
  2. Because GST is levied on the old MRP until the cap is applied.
  3. Because lower margins can cause stock-outs that push patients to costlier substitute brands.
  4. Because hospitals that relied on medicine mark-ups can raise charges for consultations, diagnostics or packages instead.
Reveal answer & explanation

Answer: D

  • The cap cuts the medicine mark-up, but a hospital with a captive patient can shift that revenue to other charges, which is Gupta's central concern.
  • A misreads the mechanism: TMR recalculates the permissible MRP from the price to stockist, so raising that price does not restore the old mark-up.
  • B is wrong: the 30% cap is calculated on MRP excluding GST.
  • C is a real risk Gupta flags, but it concerns availability of older drugs, not the main reason bills may stay high.